amt-162
·Code: AMT-162, APB-102
amt-162: developed by 1 company · 1 clinical trial tracked. Updated within the last hour.
Development Pipeline (1)
| Company | Phase |
|---|---|
| uniQure N.V. (QURE) | Phase 1/Phase 2 |
Clinical Trials (1)
A Phase 1/2, Multicenter, Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Exploratory Efficacy of Intrathecally Administered Gene Therapy AMT-162 in Adult Participants With SOD1 Amyotrophic Lateral Sclerosis (SOD1-ALS).
Frequently asked questions
Who is developing amt-162?
amt-162 is being developed by uniQure N.V..
How many clinical trials involve amt-162?
BioSniper tracks 1 clinical trial involving amt-162.
Get deeper analysis on amt-162
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
Start Free Analysis